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Acute inhalation of hypertonic saline does not
improve mucociliary clearance in all children
with cystic fibrosis
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Abstract
Background: Little is known of how mucociliary clearance (MCC) in children with cystic fibrosis (CF) and normal
pulmonary function compares with healthy adults, or how an acute inhalation of 7% hypertonic saline (HS) aerosol
affects MCC in these same children.
Methods: We compared MCC in 12 children with CF and normal pulmonary function after an acute inhalation of
0.12% saline (placebo), or HS, admixed with the radioisotope 99 mtechnetium sulfur colloid in a double-blind,
randomized, cross-over study. Mucociliary clearance on the placebo day in the children was also compared to MCC
in 10 healthy, non-CF adults. Mucociliary clearance was quantified over a 90 min period, using gamma scintigraphy,
and is reported as MCC at 60 min (MCC60) and 90 min (MCC90).
Results: Median [interquartile range] MCC60 and MCC90 in the children on the placebo visit were 15.4 [12.4-
24.5]% and 19.3 [17.3-27.8%]%, respectively, which were similar to the adults with 17.8 [6.4-28.7]% and 29.6 [16.1-
43.5]%, respectively. There was no significant improvement in MCC60 (2.2 [-6.2-11.8]%) or MCC90 (2.3 [-1.2-10.5]%)
with HS, compared to placebo. In addition, 5/12 and 4/12 of the children showed a decrease in MCC60 and
MCC90, respectively, after inhalation of HS. A post hoc subgroup analysis of the change in MCC90 after HS showed
a significantly greater improvement in MCC in children with lower placebo MCC90 compared to those with higher
placebo MCC90 (p = 0.045).
Conclusions: These data suggest that percent MCC varies significantly between children with CF lung disease and
normal pulmonary functions, with some children demonstrating MCC values within the normal range and others
showing MCC values that are below normal values. In addition, although MCC did not improve in all children after
inhalation of HS, improvement did occur in children with relatively low MCC values after placebo. This finding
suggests that acute inhalation of hypertonic saline may benefit a subset of children with low MCC values.
Trial Registration: ClinicalTrials.gov: NCT01293084
Background
Alterations in airway surface liquid (ASL) hydration [1]
and mucus with abnormal surface adhesivity and tena-
city [2] are thought to lead to impaired mucociliary
clearance (MCC) in patients with cystic fibrosis (CF).
Although MCC has been shown to be impaired in adult
patients with CF [3-5], it is not clear when the impair-
ment begins. In healthy human lungs, inhaled insoluble
material, such as bacteria, viruses, antigens and toxins,
deposits in the tracheobronchial ASL and is removed
from the lung in a matter of hours by MCC. Cough
clearance also plays an important role in removing
secretions from CF airways and, to some degree, it can
compensate for impairment in MCC.
Recently, the therapeutic use of osmotic agents, such
as hypertonic saline (HS) has been proposed to aid in
mucus clearance in patients with CF [6]. Inhaled HS
may increase airway surface fluid, reduce the abnormal
surface adhesivity and tenacity of the mucus and
improve MCC. In addition, HS may induce cough,
thereby promoting cough clearance.
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Several studies have shown that an acute inhalation of
HS improves MCC in adult patients with CF [3-5]. The
use of HS has also been shown to improve lung function
and decrease exacerbations in children and adults with
CF [7,8]. For this reason, the clinical use of HS has
increased dramatically in the past few years [9]. Despite
this rapid uptake into clinical practice, there is little
information to guide the use of HS in children with CF
who have normal pulmonary function. In this study, we
hypothesized that children with CF and normal pulmon-
ary function will have MCC values similar to healthy
non-CF individuals and will show significant improve-
ment in MCC following an acute inhalation of HS, com-
pared to placebo.
Methods
Study Design and Subject Populations
This was a double-blind, randomized, placebo-controlled
study, consisting of a screening visit and two study vis-
its. The protocol was approved by the Johns Hopkins
University Institutional Review Board (IRB). Written
informed consent was obtained from parents and either
written, or verbal assent, was obtained from the partici-
pants depending on their age.
Inclusionary criteria were: males and non-pregnant
females, age 7-14 years, diagnosis of CF by sweat chlor-
ide > 60 meq/L, or presence of two disease-causing
CFTR mutations, and FEV1 ≥ 90% of predicted values.
A group of healthy non-CF adults, who had under-
gone MCC measurements previously at Johns Hopkins,
as part of a multicenter MCC standardization protocol,
served as a comparison control group. Clearly, healthy
children without CF would have been the preferred con-
trol group for these studies. However, our IRB does not
allow healthy children to be exposed to ionizing radia-
tion for research purposes.
Concomitant Medications
Children who were taking inhaled tobramycin were stu-
died during the off-month of treatment. Children were
asked to stop bronchodilators, rhDNase (dornase-alpha),
and airway clearance therapy for 12 hours before and
during each study visit.
Sputum Induction
On the screening visit, children underwent a standar-
dized sputum induction procedure, utilized by the CF
Therapeutic Development Network [10]. Children
inhaled 3% saline for 12 min using a DeVilbiss Ultra-
Neb 99 nebulizer (Sunrise Medical, Somerset, PA). Bac-
terial and fungal cultures were carried out with any spu-
tum obtained. If sputum was not expectorated, an
oropharyngeal culture was obtained. None of the chil-
dren spontaneously produced sputum at baseline.
Placebo and Hypertonic Saline Administrations
At least one week following the screening visit, children
inhaled 5 ml of 0.12% saline (placebo) on one study
visit. During a second study visit, they inhaled 5 ml of
7% HS. The order of these two visits was randomized
and they occurred at least one week apart. Placebo and
HS aerosols were delivered by an LC Star® nebulizer
and ProNeb Ultra® compressor (PARI Respiratory
Equipment, Richmond, VA). Prior to the administration
of HS or placebo, children inhaled 2 puffs of albuterol
(Ventolin® CFC, GlaxoSmithKline, London, England)
delivered using an Aerochamber® spacer (Trudell Medi-
cal International, London, Ontario). Albuterol was admi-
nistered to minimize the development of bronchospasm
and coughing that has been reported following the
administration of HS to patients with CF [11].
We made no attempt to blind the taste of the trial
solutions. This was based on advice from our Research
Pharmacy, whose staff felt that the addition of any
masking agents to the solutions to be aerosolized could
have unknown effects on MCC.
Mucociliary Clearance Measurements
Following inhalation of HS or placebo, patients inhaled
the radioisotope 99 mtechnetium sulfur-colloid (radioaer-
osol) and underwent sequential imaging with a gamma
camera (ZLC, Siemens, Gammasonics, Des Plains, IL).
Radioaerosol was delivered by an LC Plus® nebulizer
(PARI) and DeVilbiss Pulmo Aide® compressor (Sunrise
Medical). Children inhaled 20-25 times from the nebuli-
zer starting near functional residual capacity at a flow
rate of 0.5 L/sec. During inhalation, the nebulizer was
pulsed for a fixed time of 0.7 sec. After inhalation to
total lung capacity, children exhaled immediately. There
was no breath hold.
Lung images were acquired every 2 min for the first
20 min and every 10 min for up to 90 min. Between the
60 and 90 min measurements, children coughed 30
times in two 15 cough sequences. Clearance values
reported at 60 min represented removal of radioisotope
and mucus from the airways due to MCC, while values
at 90 min represented a combination of MCC and
cough clearance. We ensured that all study patients
coughed with similar effort by monitoring their peak
expiratory flow during each cough with a PiKo-1 elec-
tronic peak flow meter (Ferraris Medical, Inc., Louisville,
CO).
Lung images were analyzed in terms of the amount of
radioactivity initially deposited in the right lung at time
0 (i.e. first lung image) and the amount of radioisotope
that was retained at each time point thereafter, using a
Sopha computer (SMV, Twinsburg, OH). Counts in the
right lung were corrected for time decay and back-
ground activity and expressed as a percentage of the
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radioactivity detected at time 0. Percent clearance was
calculated as the difference between percent radioactiv-
ity in the lung at time 0 and radioactivity remaining at
any given time point thereafter.
The central to peripheral (C:P) ratio was determined
from the time 0 image using methods that have been
described previously [12]. Larger C:P ratios indicated
greater deposition of the radioaerosol in the larger, cen-
tral airways.
Sample Size Estimate
Sample size was estimated using Stata Version 9 (Stata-
Corp, College Station, TX) and was based on MCC data
from prior studies in adolescent and young adult
patients with CF who were treated with HS [5] and
adult healthy subjects who were treated with placebo
[13]. In the former study [5], the mean difference in
MCC at 1 hour was 4.7% (post HS - baseline values). In
the latter study [13], mean MCC ± standard deviation
(SD) at 76 minutes was 12.3 ± 8.3 [13]. Since our pro-
posed analysis was a paired comparison of differences
within the same child, we assumed a range of values for
the SD of the difference in clearance between placebo
and HS that was less than the variability of independent
measurements observed in these two studies. We deter-
mined that a sample size of 12 children would provide
80% power to detect a 5% or larger mean difference in
MCC between inhalation of placebo versus HS aerosol,
assuming the SD of the paired differences was 6% and
assuming a = 0.05 (2-sided). A 5% mean difference
between treatments is similar to what was reported by
Donaldson et al. [5].
Statistical Analysis
Because of the small subject population, non-parametric
analyses were used throughout. Data are presented as
box plots showing the median and interquartile range
(IQR). The “whiskers” represent the 10th and 90th per-
centiles. Clearance values are expressed as percent MCC
at 60 min (MCC60) and at 90 min (MCC90) after inha-
lation of the radioaerosol. MCC and C:P ratios for the
children on the placebo visit and for the adults were
compared using a Wilcoxon rank sum test. The change
in MCC60 and MCC90 with HS from placebo in the
children was compared using a Wilcoxon signed rank
test. In summarizing the results, it was noticed that
some children had lower percent MCC values on the
placebo visit than others. A post hoc subgroup analysis
on the change in MCC60 and MCC90 with HS from
placebo was conducted using a median split of MCC60
and MCC90 on placebo to compare children with lower
MCC to higher MCC using a Wilcoxon rank sum test.
C:P ratios in these subgroups were also compared using
a Wilcoxon rank sum test. Non-parametric tests were
conducted using SAS version 9.22 (SAS Institute, Inc.,
Cary, North Carolina). All tests were 2-sided and signifi-
cance was set at P < 0.05.
Results
Participant Characteristics
Twelve children completed the screening visit and the
two study visits. Their characteristics are shown in
Table 1. Three additional children were enrolled, but
failed the screening visit. Two other children dropped
out after the first study visit. All screening failures and
dropouts were replaced. Airway cultures from 10
(83.3%) children grew at least one organism and cultures
from 5 children (41.7%) grew 2 organisms.
The control group consisted of 10 non-CF adults
(6 male, 4 female) without respiratory disease. Their
ages ranged between 18-37 years. Median (IQR) age was
24 (22-27) years. Median FEV1 was 103% (88-110) pre-
dicted. Median FVC was 93% (89-95) predicted.
Table 1 Characteristics of Children that Completed the
Study
Characteristic No. (%) or Median (IQR)
No. of patients 12 (100)
Age (years) 10.5 (8.9 - 12.4)
FVC (% predicted) 107 (101.5 - 116.0)
FEV1 (% predicted) 108 (102.5 - 117.5)
Height (percentile) 36.5 (16.0 - 70.5)
Weight (percentile) 39.5 (27.5 - 71.5)
BMI (percentile) 48.5 (35.0 - 69.5)
Genotype:
F508del homozygous 9 (75%)




rhDNase (dornase alpha) 11 (92%)
Salmeterol/fluticasone 7 (58%)
Azithromycin 5 (42%)
Inhaled tobramycin 2 (17%)
Organisms cultured at screening:
Staphylococcus aureus 5 (42%)
Aspergillus fumigates 3 (25%)
Normal/Mixed Respiratory Flora 2 (17%)
Pseudomonas aeruginosa 2 (17%)
Haemophilus influenza 2 (17%)
MRSA 1 (8%)
Stenotrophomonas multiphilia 1 (8%)
Paecilomyces variotll 1 (8%)
Abbreviation: IQR, interquartile range
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Deposition Pattern on Placebo Visit
Median C:P ratio on the placebo visit for all the children
was 1.67 (1.29-2.11), which was similar to the healthy
adults with a median of 1.71 (1.28-2.06).
Mucociliary Clearance on Placebo Visit
Median MCC in the children with CF on the placebo
visit was 15.4% (12.4-24.5%) at 60 min and 19.3% (17.3-
27.8%) at 90 min. These values were not significantly
different from those obtained from the 10 healthy, non-
CF adults, whose median MCC was 17.8% (6.4-28.7%)
and 29.6% (16.1-43.5%) at 60 and 90 min, respectively.
Nevertheless, 10/12 children showed MCC90 values less
than the median observed in the adults.
Effect of Hypertonic Saline on Mucociliary Clearance
Figure 1 shows MCC60 after placebo and HS inhala-
tion for each child. Five of twelve children showed a
decrease in MCC60 after inhalation of HS. Four of
twelve children demonstrated a decrease in MCC90
after inhalation of HS (data not shown). Figure 2
shows the distribution of MCC60 for all children post
placebo and HS. The median change on HS compared
to placebo was 2.2% (-6.2-11.8%; p = 0.62). Figure 3
shows the distribution of MCC90 for all children post
placebo and HS. The median change was 2.3% (-1.2-
10.5; p = 0.32).
Post Hoc Analysis: Change in Mucociliary Clearance with
HS Compared to Placebo in Children with Low Versus
Higher MCC
The distribution of MCC60 and MCC90 for the sub-
groups after placebo and HS are presented in Figures 2
and 3, respectively. The median change in MCC60 for
the lower MCC60 group was 6.8 (1.8-13.3) and in the
higher group was -6.2 (-7.6-2.6). The difference in the
groups did not reach statistical significance (p = 0.09).
The median change in MCC90 for the lower MCC90
group was 10.0 (4.6-13.3) and in the higher group was
-1.2 (-3.9-0.0). The difference in the groups was statisti-
cally significant (p = 0.045).
Post Hoc Analysis: Aerosol Deposition Pattern in Children
with Low Versus Higher MCC on Placebo
The initial aerosol deposition pattern for children with
lower MCC60 on the placebo visit was similar to that of
children with higher MCC60 on the placebo visit. Med-
ian C:P ratio was 1.71 (1.21-2.27) and 1.67 (1.36-1.94)
for children with lower and higher MCC60 on the
placebo visit, respectively (p = 0.94).
Discussion
We undertook the current study to quantify MCC in
children with CF who have normal pulmonary function
and to determine if HS improves MCC. We found that
median percent MCC60 (15.4%) and MCC90 (19.3%) on
the placebo visit in all children with CF and normal
lung function was similar to that of the healthy, non-CF
adults. Nevertheless, 10/12 children showed MCC90
values less than the median of 29.6% observed in the
adults. These data suggest that percent MCC varies sig-
nificantly between children with CF lung disease and
normal pulmonary functions, with some children
Figure 1 Effect of hypertonic saline inhalation on mucociliary
clearance in individual children (Red - Female patients; Blue -
Male patients).
Figure 2 Box plots showing median and interquartile range for
mucociliary clearance at 60 min on the placebo and HS visits
for all children and for subgroups of children with less than or
greater than the median MCC60 after placebo. The “whiskers”
represent the 10th and 90th percentiles. Open circles represent data
outside the 10th and 90th percentiles. The change in MCC with HS
was not significantly different from placebo for all children, or for
the subgroup comparison.
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demonstrating MCC values within the normal range and
others showing MCC values that are below normal
values.
These findings are consistent with previous results
reported by Mortensen et al. in separate studies of chil-
dren with CF and healthy adults [14,15]. Mean whole
lung clearance at 60 min was 21.1 ± 13.3% in 10 chil-
dren with CF (11 ± 2 yrs) who were treated with a
metered dose inhaler containing the placebo for terbuta-
line (i.e. no drug) [14]. Median peripheral lung zone
clearance at 120 min was 18% (range 12-28%) in 10
healthy subjects who were treated with the same placebo
(median age = 30.5 yrs; range = 22-63 yrs) [15]. Nasal
MCC also appears to be similar in children with CF and
children with no respiratory disease. McShane et al. [16]
demonstrated that median nasal MCC was 11 min
(range 8-15) in 18 children with CF (median age = 11
yrs; range = 9-15 yrs), compared to 11 min (range 9-16)
in 21 children (median age = 12 yrs; range = 9.5-16)
with no respiratory disease.
Compared to placebo, an acute inhalation of hyper-
tonic saline did not significantly improve MCC in chil-
dren in this study. This finding is in contrast to
previous studies in which adults with CF demonstrated
an improvement in MCC after an acute inhalation of
HS [3-5]. However, patients in those studies had signifi-
cantly worse lung function than the majority of children
in this study and such patients may respond differently
to HS.
The notion that some patients with CF may respond
differently to HS than others is also suggested by the
significant improvement in MCC90 after HS in children
with lower MCC90 on the placebo visit in this study,
compared to children with higher MCC90 values after
placebo (Figure 3). It is also interesting that all 5 males
in the study showed improvement in MCC60 after HS
(Figure 1: blue data lines) and in MCC90 (data not
shown). In addition, all 5 males had MCC90 values less
than the median split value of 19.3% on the placebo
visit. In contrast, only 2 of 7 female children showed
improvement in MCC60 (Figure 1) and MCC90 (data
not shown) after HS, while 6 of 7 female children had
MCC90 values greater than the median split on the pla-
cebo visit. Additional studies are needed to explore the
effect of HS on patients with low MCC after placebo
and the observed gender differences in MCC and possi-
ble effects of HS.
Another possible explanation for the observed differ-
ences in MCC90 after HS, compared to placebo, for
children with lower versus higher MCC90 could involve
where the radiolabeled aerosol initially deposited in the
lungs. Aerosol that initially deposits in the larger, central
airways will be cleared faster than aerosol that is depos-
ited more peripherally because the transit path for
removal from the lungs is shorter. However, the initial
C:P ratio, an indicator of deposition pattern within the
lung, was similar for children with low and higher MCC
values. Therefore, differences in the site of deposition
cannot account for the observed differences in MCC.
One explanation for the lack of improvement in MCC
in more children in our study may be that a single dose
of HS is inadequate to show an MCC benefit. In the
study of Donaldson et al. [5], MCC improved in patients
who were treated 4 times a day with HS for 2 weeks.
Similarly, Elkins et al. [7] reported that FEV1 rose over
four weeks of therapy with HS, implying a cumulative
benefit of therapy. Similar results have been seen in
early trials of Denufosol, a therapy designed to increase
airway surface liquid hydration [17].
Also other measurements may be better at detecting
the effects of HS in children with CF who have normal
pulmonary function. This hypothesis is suggested by the
results of a recent study by Amin and colleagues [18],
who used lung clearance index (LCI), a measure of ven-
tilation non-homogeneity. They studied 19 CF patients
with a mean age of 10.5 ± 3.1 years and a mean FEV1 of
96 ± 12% predicted and found a significant improve-
ment in LCI after 4 weeks of HS compared to treatment
with isotonic saline. Again, this significant improvement
could have been the result of a longer treatment time,
compared to our acute treatment study. It could also be
that LCI is a more sensitive indicator of the treatment
Figure 3 Box plots showing median and interquartile range for
mucociliary clearance at 90 min on the placebo and HS visits
for all children and for children with less than or greater than
the median MCC90 after placebo. The “whiskers” represent the
10th and 90th percentiles. Open circles represent data outside the
10th and 90th percentiles. The change in MCC with HS was not
significantly different from placebo for all children, but was
significantly different for the comparison of the subgroups
(p = 0.045).
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effect of HS in children with mild CF lung disease than
MCC.
There are a few limitations to our study. First, our
sample size calculation, based on a paired t-test with a
known standard deviation of 6, resulted in a sample size
of 12 subjects to have 80% power using a two-sided test
with Type I error set at 0.05. However, the observed
standard deviation was 12 and for this reason the study
was likely underpowered. Secondly, it is possible that
some of the patients may have become unblinded, since
the taste of HS was salty compared to the placebo.
However, the MCC measurements should not have been
affected by this differentiation, since MCC measure-
ments are involuntary and do not depend on the
patient’s effort. Also, the person who performed the
data analysis was blinded to the administered solutions.
Another limitation is that 10/12 children grew at least
one organism after culturing their lung sputum and
those organisms may have affected MCC. However, stu-
dies of MCC in children infected with specific organ-
isms have not been performed, so the possible affect of
these organisms on MCC in children in this study can-
not be evaluated. Another limitation was that our con-
trol group was an adult population, rather than healthy
children. However, their MCC was similar to our CF
sample and was consistent with other studies. Finally,
we only administered one dose of HS, which may not
have been sufficient to elicit significant improvement in
MCC in some patients.
Conclusions
These data suggest that percent MCC varies significantly
between children with CF lung disease and normal pul-
monary functions, with some children demonstrating
MCC values within the normal range and others show-
ing MCC values that are below normal values. In addi-
tion, although MCC did not improve in all children
after inhalation of HS, improvement did occur in chil-
dren with relatively low MCC values after placebo. This
finding suggests that acute inhalation of hypertonic sal-
ine may benefit a subset of children with low MCC
values.
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